MedSci Healthcare
The company has done projects with major companies such as: Pfizer, Harvard Medical School, AstraZeneca, GSK, Abbott, Johnson & Johnson, Takeda, Novartis, Medtronic and many more. We have also worked with organizations such as the China Cardiovascular Association (CCA), Chinese Medical Doctor Association (CMDA) and more.
MedSci is a digital academic platform, scientific publishing support and multichannel marketing (MCM) organization. We use the term Academic Promotion Organization (APO). We use scientific writers, doctors & researcher scientists and commercialization experts to develop customized strategy & implementation to reach each organization’s goals.
Chad Gloetzner
VP of Sales and OperationsMedTravo
MedTravo is an online Global Medical Tourism marketplace for an International Medical Travelers Globally which connects patients to the Right Healthcare Providers and Doctors in India, UAE and other 8 South Asian countries in the world. We have helped 2000 patients till date through us who have been to different destinations for their Medical Treatment/ Surgery.
Mr. Adil Saghir
Chief Executive OfficerMedWorld Advisors
Dave Sheppard
Managing DirectorMesa Verde Venture Partners
Mr. Randy Berholtz
Senior AdvisorMicar Innovation (Micar21)
Micar Innovation is a drug discovery factory. The company has found a niche where it is able to create a large societal impact by improving the quality of life through discovery novel blockbuster drug molecules for a large class of diseases (Pipeline). Micar Innovation focuses on entire drug discovery process using improved structure based insilico drug design from scratch till Preclinical phase with advanced predictions of activity, selectivity and ADMET.
MID LABS
MID Labs continues to innovate with the MID Labs branded product line which is supplied to more than 30 countries around the world. These products set the standard for precision, performance, and quality.
Dr. Kai Chen
CEOMIMETAS Organ on a chip company
MIMETAS BV develops organ-on-a-chip tissue models for evaluating drugs, chemicals and food components. Its unique microfluidic technology, designated OrganoPlates®, enables testing of compounds in high-throughput on miniaturized organ models. These models show better predictivity as compared to laboratory animals and conventional cell culture models. The OrganoPlate® platform supports 3D cell culture under continuous perfusion and membrane-free co-culture, including epithelial and endothelial boundary tissues. MIMETAS offers OrganoPlates®, develops and validates customised disease, toxicology and transport models and will ultimately make her technology available for personalised therapy selection.
Mr. Luc Zhang
VP Great ChinaMira Life Science Ventures
Mira Life Science Ventures was established to change the paradigm for investment, incubation and development of new disruptive and game-changing technologies in the life sciences. Mira LSV will invest in medical devices, therapeutics, diagnostics, enabling technologies and digital healthcare. Mira LSV will focus its efforts in areas of significant unmet medical needs such as cancer, neurological diseases, infectious disease, autoimmune disease, inflammatory diseases, personalized medicine, cardiovascular disease and renal diseases.
In order to change the venture investment paradigm, Mira LSV was formed to break out of the traditional venture model and move to a more flexible, nimble and shareholder-centric model to accelerate development of these break-through products and technologies and bring them to patients. Mira LSV’s highly flexible business structure, broad and diverse access to deal-flow and highly experienced management team will ensure we have a significant positive impact on our healthcare system.